

Independent Medical Education Grants

1st Jul 2015 – 30th Sep 2015

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Academic CME, LLC	APPLYING ADVANCED TREATMENT STRATEGIES WITHIN RHEUMATOID ARTHRITIS	326,430 Collaboration ³
AKH Inc. Advancing Knowledge and Healthcare Florida Society of Rheumatology	FLORIDA SOCIETY OF RHEUMATOLOGY 2015 ANNUAL CME CONFERENCE	5,000
American Academy of Continuing Medical Education, Inc.	TRANSLATING CLINICAL DATA INTO NEPHROLOGY PRACTICE IN THE MANAGEMENT OF HYPERPHOSPHATEMIA	149,800
American Association of Clinical Endocrinologists	HEARTLAND-AAACE 6TH ANNUAL MEETING	7,500
American Association of Clinical Endocrinologists	ILLINOIS CHAPTER OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 5TH ANNUAL METING	5,000
American Association of Diabetes Educators Horizon CME, Inc.	INHALED INSULIN A BREATH OF FRESH AIR FOR THE TREATMENT OF DIABETES	62,800
American Diabetes Association	30TH ANNUAL CLINICAL CONFERENCE ON DIABETES: BEYOND THE NUMBERS	25,000
American Diabetes Association	DIABETES AND ENDOCRINE DISORDERS FOR THE GENERALIST AND SPECIALIST	5,000
American Diabetes Association	TRANSITIONS OF CARE THROUGH THE DIABETES LIFESPAN	5,000
American Society of Nephrology	ASN BOARD REVIEW COURSE AND UPDATE	15,000
American Society of Nephrology	CALCIUM OR NO CALCIUM: THAT IS THE QUESTION	125,825

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2015 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jul 2015 – 30th Sep 2015

Recipient Name(s) ¹	Activity Title	Funding Amount ²
American Urological Association Education & Research, Inc.	ESTABLISHING AN ADVANCED PROSTATE CANCER CLINIC: A PRACTICAL GUIDE FOR THE UROLOGY CLINIC	60,000
Association of Family Practice Physician Assistants	JOINT ASPIRATION/INJECTION WORKSHOP	5,300
Cardiovascular Society of Buffalo and Western NY SUNY AT BUFFALO CME OFFICE	UNDERSTANDIJG FABRY DISEASE FROM A CARDIAC PERSPECTIVE	7,000
Cleveland Clinic Educational Foundation	CURRENT AND FUTURE THERAPEUTIC OPTIONS TARGETING RESIDUAL CVD RISK: EMERGING THERAPIES FOR THE TREATMENT OF DYSLIPIDEMIA	80,000 Collaboration ³
CME Outfitters, LLC	RISKY BUSINESS: UNDERSTANDING AND ATTENUATING RISK ASSOCIATED WITH DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS	207,090
Consortium of Multiple Sclerosis Centers Nurse Practitioner Alternatives	EXPERT DEBATES IN MULTIPLE SCLEROSIS: OPPOSING VIEWS IN MANAGEMENT	125,000
Consortium of Multiple Sclerosis Centers Nurse Practitioner Alternatives	PATIENTGPS?: CLINICAL PATHS TO EXPLORE TREATMENT OPTIONS AND INDIVIDUALIZE THERAPY IN MULTIPLE SCLEROSIS	100,000
Dignity Health MandatoryCE LLC	2ND ANNUAL NEW MEXICO REGIONAL DIABETES SYMPOSIUM	45,000
FORE	2015 ORTHOPAEDICS FOR THE PRIMARY CARE PRACTITIONER & REHABILITATION THERAPIST	4,000
Humboldt-Del Norte Consortium for Continuing Medical Education	MULTIPLE SCLEROSIS	4,100
Icahn School of Medicine at Mount Sinai	MULTIPLE SCLEROSIS AND ITS MIMICS	1,920
Icahn School of Medicine at Mount Sinai	ADVANCES IN PEDIATRIC FOOD ALLERGY	15,000
Institute for the Advancement of Human Behavior Answers in CME, Inc.	LEARNER-DIRECTED CME: WHAT DO PRIMARY CARE PROVIDERS NEED TO KNOW ABOUT THE LATEST ADVANCES IN THE TREATMENT HYPERCHOLESTEROLEMIA	49,500

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2015 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jul 2015 – 30th Sep 2015

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Johns Hopkins University Advanced Studies in Medicine	THE 11TH ANNUAL JOHNS HOPKINS MULTIPLE SCLEROSIS SYMPOSIUM SERIES	210,000
Johns Hopkins University Advanced Studies in Medicine	COMPREHENSIVE CARE FOR PATIENTS WITH GAUCHER DISEASE: EMERGING CONCEPTS FOR IMPROVED OUTCOMES	195,100
Johns Hopkins University Medical Logix, LLC	MANAGEMENT OF PERSISTENT HYPERGLYCEMIA IN TYPE 2 DIABETES: BEYOND STARTING DOSES OF BASAL INSULIN	81,750
Medical Education Resources Tarsus Cardio Inc. dba Health Science Media	THE EVOLUTION OF INSULIN THERAPY: NEW DEVELOPMENTS IN TREATMENT, TECHNOLOGY, AND METHODS OF ADMINISTRATION	100,000
Medical Learning Institute, Inc. PeerView Institute for Medical Education, Inc.	PEERVIEW INREVIEW, RISING TO THE CHALLENGE: FOSTERING EFFECTIVE PATIENT-PROVIDER COMMUNICATION THROUGHOUT THE COURSE OF POMPE DISEASE	100,000
Medical University of South Carolina	1ST ANNUAL NEPHROLOGY TRANSPLANT SYMPOSIUM FOR NEPHROLOGISTS, PRIMARY CARE AND HOSPITALISTS	2,500
Med-IQ, LLC	TARGETING MODERATE-TO-SEVERE ATOPIC DERMATITIS: EVOLVING TREATMENT STRATEGIES TO ADDRESS A KEY UNMET MEDICAL NEED	99,896
Med-IQ, LLC	CASE SIMULATIONS IN TUMOR LYSIS SYNDROME: AGGRESSIVE PROPHYLAXIS STRATEGIES TO PREVENT ADVERSE PATIENT OUTCOMES	Collaboration ³
Med-IQ, LLC	UPDATE FOR CLINICIANS: THE POTENTIAL OF IL-6 INHIBITORS TO REVOLUTIONIZE RHEUMATOID ARTHRITIS TREATMENT	104,578
Medscape, LLC	A PRACTICAL GUIDE TO THE PREVENTION OF SURGICAL ADHESIONS	Collaboration ³
Medscape, LLC	IDENTIFYING AND ADDRESSING INADEQUATELY MANAGED OSTEOARTHRITIS PAIN	160,000
Medscape, LLC	GLP-1 RECEPTOR AGONISTS IN T2D MANAGEMENT: THE MODERN INJECTABLE	138,500
Missouri Academy of Physician Assistants	THE GOOD, THE BAD, AND THE IATROGENIC?	105,100
		3,500

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2015 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jul 2015 – 30th Sep 2015

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Missouri Academy of Physician Assistants	JOINT INJECTIONS	5,000
Montefiore Medical Center	A COMPREHENSIVE PERSPECTIVE ON INSULIN REPLACEMENT FOR TYPE 2	
PlatformQ Health Education, LLC	DIABETES	100,000
Montefiore Medical Center	MULTIPLE SCLEROSIS: EXPLORING TREATMENT OPTIONS AND INDIVIDUALIZING	
PlatformQ Health Education, LLC	THERAPY	85,000
National Association of Managed Care Physicians, Inc.	ADVANCES IN THE MANAGEMENT OF MULTIPLE SCLEROSIS: A CLOSER LOOK AT NOVEL THERAPIES	57,000
National Association of Managed Care Physicians, Inc.	INDIVIDUALIZING TREATMENT STRATEGIES FOR EFFECTIVE A1C REDUCTION AND IMPROVED OUTCOMES IN TYPE 2 DIABETES	57,000
National Jewish Health		10,000
California Society of Allergy, Asthma and Immunology	CSAAI 23RD ANNUAL EDUCATIONAL MEETING	Collaboration ³
National Kidney Foundation, Inc.	GREENSBORO PATIENT EMPOWERMENT WORKSHOP	3,500
National Kidney Foundation, Inc.	CHRONIC KIDNEY DISEASE & THE PRIMARY CARE PRACTITIONER: EARLY SCREENING AND PREVENTION FOR THE AT-RISK PATIENT	
National Kidney Foundation, Inc.		25,000
National Kidney Foundation, Inc.	11TH ANNUAL JOINT MEETING OF THE UPSTATE AND WESTERN NEW YORK COUNCILS ON RENAL NUTRITION	5,000
National Medical Association	NEW TYPE 2 DIABETES GUIDELINES AND THE TREND TOWARD NEWER PHARMACOLOGICAL TREATMENT	100,000
North American Center for Continuing Medical Education, LLC		
Horizon CME, Inc.	IMPLEMENTING BEST PRACTICES FOR TUMOR LYSIS SYNDROME	100,000
Not-For-Profit Hospital Corporation	CHRONIC KIDNEY DISEASE: STATE OF THE ART 2015	1,900
Pennsylvania Academy of Family Physicians Foundation	PA ACADEMY OF FAMILY PHYSICIANS FOUNDATION A1C CHALLENGE	150,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2015 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jul 2015 – 30th Sep 2015

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Pennsylvania Society of Physician Assistants	THYROID MASSES	8,400
Pharmacy Times Office of Continuing Professional Education	CONVENIENT CARE OPPORTUNITIES TO OPTIMIZING INSULIN THERAPY IN TREATMENT OF TYPE 2 DIABETES	48,689
Pharmacy Times Office of Continuing Professional Education PQA, Inc.	AJPB QUALITY FORUM: IMPLEMENTATION OF QUALITY MEASURES TO IMPROVE OUTCOMES IN DYSLIPIDEMIA	50,000 Collaboration ³
Pharmacy Times Office of Continuing Professional Education PQA, Inc.	AJPB QUALITY FORUM: AIMING FOR A FIVE-STAR RATING IN DIABETES CARE: MANAGED CARE PLANS AND COMMUNITY PHARMACIST COLLABORATION	50,000
Postgraduate Healthcare Education, LLC Medical Logix, LLC	ADDRESSING HYPOGLYCEMIA IN TYPE 2 DIABETES MELLITUS: THE PHARMACISTS ROLE IN OPTIMIZING PATIENT OUTCOMES	30,000
Postgraduate Institute for Medicine C-MEducation Resources, LLC	NOVEL MECHANISMS AND ADVANCING THERAPEUTIC PARADIGMS FOR OPTIMIZING LDL-FOCUSED MANAGEMENT AND CARDIOPROTECTION IN THE DIABETIC PATIENT	379,000 Collaboration ³
Postgraduate Institute for Medicine C-MEducation Resources, LLC	THE IQ&A INTERACTIVE CARDIOVASCULAR INTELLIGENCE ZONE: NEW FRONTIERS IN LDL-TARGETED CV RISK REDUCTION	238,100 Collaboration ³
Preventive Cardiovascular Nurses Association	2015 FALL LEARNING SERIES	35,000
PRIME Education Inc. (PRIME)	CASE-BASED DEBATES ABOUT UTILITY OF PCSK9 INHIBITORS IN PATIENT POPULATIONS FOR LIPID REDUCTION	123,000 Collaboration ³
PRIME Education Inc. (PRIME)	INTERNATIONAL INSIGHTS ON TREATMENT ADVANCES FOR RHEUMATOID ARTHRITIS	166,077 Collaboration ³
PRIME Education Inc. (PRIME)	NEW CHALLENGES IN THE PREVENTION AND MANAGEMENT OF TUMOR LYSIS SYNDROME IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	78,810
Pri-Med Institute, LLC (d/b/a pmiCME) Horizon CME, Inc.	DYSLIPIDEMIA IN PRIMARY CARE: NEW GUIDELINE RECOMMENDATIONS AND TREATMENT OPTIONS	250,000 Collaboration ³
ProCE, Inc. Institute for Safe Medication Practices	CONCENTRATED INSULIN: SAFE USE IN THE HOSPITAL AND TRANSITIONS OF CARE	102,233

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2015 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jul 2015 – 30th Sep 2015

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Projects In Knowledge, Inc.	MULTIPLE SCLEROSIS @ POINT OF CARE	200,000
Regents of the University of Colorado	RENAL DISEASE & ELECTROLYTE DISORDERS COURSE	3,000
Regents of the University of Colorado American Thyroid Association	PEDIATRIC AND ADULT DIFFERENTIATED THYROID CANCER, ARE THEY DIFFERENT?	75,000
Regents, University of California	THIRD ANNUAL UCLA REVIEW OF CLINICAL NEUROLOGY DEVELOPING AN INTEGRATIVE APPROACH TO METASTATIC PROSTATE CANCER: MAKING IT PERSONAL TO IMPROVE CLINICAL OUTCOMES	15,000
Rush University Medical Center Plexus Communications		65,000
Rutgers, The State University of New Jersey Global Academy for Medical Education, LLC	8TH ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES, PRESENTED BY RHEUMATOLOGY NEWS, INTERNAL MEDICINE NEWS, FAMILY PRACTICE NEWS	10,000 Collaboration ³
South Dakota Academy of Physician Assistants	DIABETIC MANAGEMENT	3,500
Tennessee Academy of Physician Assistants	FALLFEST 2015-RENAL DISEASE	2,500
Texas A&M University System Health Science Center Coastal Be	11TH ANNUAL DIABETES CONFERENCE	10,000
The Boston Home	CARING FOR THE PATIENT WITH ADVANCED MULTIPLE SCLEROSIS	10,000
The Endocrine Society	UPDATE IN BASAL INSULINS: YOUR QUESTIONS ANSWERED	129,040
The Endocrine Society	2015 CLINICAL ENDOCRINOLOGY UPDATE	25,000
The Endocrine Society	2015 CLINICAL ENDOCRINOLOGY UPDATE	25,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2015 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jul 2015 – 30th Sep 2015

Recipient Name(s) ¹	Activity Title	Funding Amount ²
The France Foundation	MS CLINICAL DIALOGS: A PEER DISCUSSION ON OPTIMAL TREATMENT (PHASE 2)	76,547
The France Foundation National Society of Genetic Counselors	A MULTI-DISCIPLINARY APPROACH TO LIMB-GIRDLE MUSCLE WEAKNESS DYSTROPHY AND RELATED CONDITIONS MANAGEMENT INTERACTIVE UPDATES IN USE OF STEM CELL MOBILIZATION FOR THE TREATMENT OF BLOOD RELATED CANCERS	240,794
The Medical College of Wisconsin, Inc. Carden Jennings Publishing Co., Ltd.	IMPROVING OUTCOMES IN RHEUMATOID ARTHRITIS: TREATING TO TARGET, IL-6- DIRECTED THERAPIES, AND EVOLVING MANAGEMENT ALGORITHMS	120,000
Ultimate Medical Academy, LLC dba Global Education Group Integritas Communications, LLC	THE CHANGING LANDSCAPE OF DYSLIPIDEMIA TREATMENT	162,588 Collaboration ³
UMA MLG, LLC	A 3-DIMENSIONAL VIEW INTO THE ROLE OF GLP1 IN TYPE-2 DIABETES: EXPLORING EVIDENCE-BASED GUIDELINES AS PATIENT-CENTERED THERAPY	198,900 Collaboration ³
UMA MLG, LLC	PROMOTING BEHAVIOR CHANGE IN DIABETES: A SKILL BUILDING PROGRAM FOR HEALTH CARE PROFESSIONALS A	30,000
University of California, San Diego Behavioral Diabetes Institute	THE KNEE COURSE 2015	50,000
University of Cincinnati Global Academy for Medical Education, LLC	RENAL PHYSICIANS ASSOCIATION 2015 ADVANCED PRACTITIONER CONFERENCE	19,500
University of Virginia Renal Physicians Association		12,500

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2015 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.